Paul Tudor Jones Celldex Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 32,545 shares of CLDX stock, worth $662,290. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,545Holding current value
$662,290% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding CLDX
# of Institutions
197Shares Held
69.7MCall Options Held
960KPut Options Held
675K-
Wellington Management Group LLP Boston, MA8.98MShares$183 Million0.04% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.06MShares$103 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$95.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$79 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$76.4 Million1.82% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $952M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...